Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Medullary breast carcinoma (MBC) is a rare, yet clinically distinct subtype of breast cancer, accounting for approximately 1-7% of all invasive breast cancer cases. At Alfa Cytology, our team of experienced biologists work with you to develop MBC therapeutics.
Traditionally, MBC has been considered an aggressive form of breast cancer, owing to its high nuclear grade and triple-negative receptor status (lacking expression of estrogen receptor, progesterone receptor, and HER2). However, the clinical course of MBC often defies this expectation. Contrary to the poor prognosis typically associated with triple-negative breast cancer, MBC has been shown to have a favorable overall survival, with 5-year survival rates ranging from 70-90%.
Fig.1 Main histopathology, markers, and signalling pathways of medullary breast carcinoma. (Mahmoud R., et al. 2022)
Traditionally, the management of MBC has relied on standard treatment modalities used for other breast cancer subtypes, such as surgery, radiation therapy, and systemic chemotherapy. However, the unique biological characteristics of MBC have led to the exploration of more targeted and personalized therapeutic strategies.
| Category | Therapeutics | Phase | NCT |
| Combination Therapies | G1T38, a CDK 4/6 Inhibitor, in Combination with Fulvestrant | NCT02983071 | |
| Trastuzumab + Pertuzumab + Vinorelbine, Paclitaxel, Nab-Paclitaxel, Docetaxel, Capecitabine | NCT02229149 | ||
| Targeted Therapy | X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 | NCT00558545 |
Medullary breast carcinoma is a relatively rare disease but malignant. Multiple factors influence prognosis and therapy options. Therefore, Alfa Cytology is working on providing one-stop solutions for medullary breast carcinoma, including but not limited to the following.
MBC Therapy Development
If your research requires specialized MBC models, our team can work with you to build novel in vitro and in vivo systems to support our clients' drug discovery and translational research efforts.
| MBC Cell Lines | Animal Models of MBC |
|
|
Alfa Cytology is committed to the research and study of MBC, from molecular biology services, and cancer biomarker discovery services, to preclinical research services, providing one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for MBC. If you are interested in our service, please contact us.
Reference
